AstraZeneca: Lynparza Trial Has Met Primary Endpoint

Features Dow Jones Newswires

AstraZeneca PLC (AZN.LN) said Monday that the phase 3 trial of treatment drug Lynparza has met its primary endpoint.

Continue Reading Below

The pharmaceutical company said the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival for patients treated with Lynparza tablets, compared to chemotherapy.

Write to Tapan Panchal at tapan.panchal@wsj.com

(END) Dow Jones Newswires

June 05, 2017 02:32 ET (06:32 GMT)